JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases
Abstract
Objective: Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome usually involves bones, joints, and skin. Due to a lack of known pathogenesis and clinical trials, there is no standard treatment of SAPHO syndrome. Because none of the current treatments have a high efficacy and the risk of relapse is high, new treatment options for SAPHO syndrome are necessary. JAK inhibitors (JAK-I) are a group of small-molecule drugs with a wide range of effects on inflammatory and autoimmune pathways.
Methods: A systematic search was conducted using medical subject headings terms or keywords related to JAK-I and SAPHO syndrome through PubMed/Medline, Scopus, Web of Science, and Embase until September 8, 2024. The inclusion criteria included a patient diagnosed with SAPHO syndrome who received at least one JAK-I. We excluded reviews and animal studies.
Results: Of 287 initially researched articles, we included 34 articles. These 34 articles represent 72 patients with a mean age of 39.36 years. Of these, 56 (78%) were female. All patients had bone or joint involvement, and 64 patients had skin involvement. Seventy patients (97.2%) had received at least one treatment before using JAK-I. All patients received just one JAK-I. Of these, 54 (75%) received tofacitinib, 15 (20.8%) received baricitinib, and 3 (4.2%) received upadacitinib. All patients except one (98.6%) showed good to complete response. Ten patients (13.9%) showed a clinical adverse effect. All were taking…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 72 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.